STUDY OBJECTIVE: To characterize the concentration-time profiles of zidovudine and zidovudine-glucuronide in semen and serum of men infected with the human immunodeficiency-1 virus (HIV-1). DESIGN: Open-label observational study. SETTING: University-affiliated teaching hospital and research center. PATIENTS: Four asymptomatic HIV-1-infected men. INTERVENTIONS: Zidovudine administration was followed by an 8-hour intensive pharmacokinetic study on day 1. Over the next 8 days, a dose administration and timed single-sample strategy was employed to determine serum and semen concentration time profiles simultaneously. MEASUREMENTS AND MAIN RESULTS: Zidovudine and zidovudine-glucuronide concentrations were uniformly higher in semen than in serum except at 1 hour after the dose. The median area under the curve ratio (semen AUC0-48:serum AUC0-infinity) was 3.31 for zidovudine and 15.04 for zidovudine-glucuronide. CONCLUSION: Zidovudine and zidovudine-glucuronide reach high levels in seminal plasma relative to serum. The virologic, pharmacodynamic, and public health implications of distribution to this compartment require further study.
STUDY OBJECTIVE: To characterize the concentration-time profiles of zidovudine and zidovudine-glucuronide in semen and serum of men infected with the humanimmunodeficiency-1 virus (HIV-1). DESIGN: Open-label observational study. SETTING: University-affiliated teaching hospital and research center. PATIENTS: Four asymptomatic HIV-1-infectedmen. INTERVENTIONS:Zidovudine administration was followed by an 8-hour intensive pharmacokinetic study on day 1. Over the next 8 days, a dose administration and timed single-sample strategy was employed to determine serum and semen concentration time profiles simultaneously. MEASUREMENTS AND MAIN RESULTS:Zidovudine and zidovudine-glucuronide concentrations were uniformly higher in semen than in serum except at 1 hour after the dose. The median area under the curve ratio (semen AUC0-48:serum AUC0-infinity) was 3.31 for zidovudine and 15.04 for zidovudine-glucuronide. CONCLUSION:Zidovudine and zidovudine-glucuronide reach high levels in seminal plasma relative to serum. The virologic, pharmacodynamic, and public health implications of distribution to this compartment require further study.
Authors: Julie B Dumond; Kuo H Yang; Racheal Kendrick; Y Sunila Reddy; Angela D M Kashuba; Luigi Troiani; Arlene S Bridges; Susan A Fiscus; Alan Forrest; Myron S Cohen Journal: Antimicrob Agents Chemother Date: 2015-08-03 Impact factor: 5.191
Authors: R M van Praag; S Repping; J W de Vries; J M Lange; R M Hoetelmans; J M Prins Journal: Antimicrob Agents Chemother Date: 2001-10 Impact factor: 5.191
Authors: Julie B Dumond; Y Sunila Reddy; Luigi Troiani; Jose F Rodriguez; Arlene S Bridges; Susan A Fiscus; Geoffrey J Yuen; Myron S Cohen; Angela D M Kashuba Journal: J Acquir Immune Defic Syndr Date: 2008-06-01 Impact factor: 3.731
Authors: David M Klein; Kristen K Evans; Rhiannon N Hardwick; William H Dantzler; Stephen H Wright; Nathan J Cherrington Journal: J Pharmacol Exp Ther Date: 2013-05-02 Impact factor: 4.030